Its Phase 2 obesity trial published in Lancet Diabetes & Endocrinology (2024) showed up to 18.7% weight loss at 46 weeks, while a separate Phase 2 MASH trial demonstrated significant MASH resolution, earning FDA Breakthrough Therapy Designation
These mechanisms occur within hours after GCs administration and may lead to hyperglycemia, even in individuals without a prior history of glucose abnormalities ( Figure 1 The clinical impact of hyperglycemia during GCs therapy has been well established, with multiple studies reporting increased morbidity and mortality, including higher rates of infection, cardiovascular events and prolonged hospitalisations ( Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are not currently recommended in SID by major guidelines, their mechanism of action makes them promising candidates to counteract the metabolic impacts of steroids
Once approved, youll begin a weekly injection regimen, with personalized guidance on self-injection techniques, ongoing monitoring, and dedicated support
We will print it for you on matte photo paper to keep forever.
The monitoring is the part that makes it defensible, because your own response data does the job the missing trial hasn't done yet
Our microdosing tirzepatide chart outlines exactly how this sub-therapeutic introduction phase works
